A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)
A phase 3 trial testing YL201 in nasopharyngeal carcinoma, active and no longer recruiting.
Overview
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301) is a phase 3 interventional study registered as NCT06629597, led by MediLink Therapeutics (Suzhou), and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, Controlled, Multicenter Phase III Clinical Study of YL201 Versus Investigator's Choice of Chemotherapy in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Failed Prior PD-(L)1 Inhibitor and at Least Two Lines of Chemotherapy. Planned enrolment is 400 participants (estimated). The study started in 2024-12-31 and primary completion is expected in 2027-12-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
Shares YL201, MediLink Therapeutics and the tag ctgov-ingest.
- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares YL201, MediLink Therapeutics and the tag ctgov-ingest.
- TrialPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TrialYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TrialKL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.
- TreatmentYL202
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TreatmentKL-A167
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.
- TreatmentMRG003
Shares Nasopharyngeal carcinoma and the tag ctgov-ingest.